- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05877599
En studie av NT-175 hos vuxna försökspersoner med icke-opererbara, avancerade och/eller metastaserande fasta tumörer som är positiva för HLA-A*02:01 och TP53 R175H-mutationen
En öppen fas 1, multicenterstudie för att utvärdera säkerheten och preliminär antitumöraktivitet av NT-175 i humant leukocytantigen-A*02:01-positiva vuxna försökspersoner med icke-opererbara, avancerade och/eller metastaserande fasta tumörer som är Positivt för TP53 R175H-mutationen
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 1, open-label, multicentre platform study to evaluate the safety and preliminary antitumour activity of NT-175 in HLA-A*02:01 participants with advanced malignancies that are positive for the TP53 R175H mutation.
Dose Escalation will investigate escalating doses of NT-175 in adult subjects with eligible histologies and will evaluate the safety and MTD and/or RDE/RP2D.
Cohort expansion will further evaluate the safety and preliminary anti-tumour activity at or below the MTD in disease specific histologies and determine the RP2D.
Dose Expansion will further evaluate the preliminary anti-tumour activity and safety of NT-175 at the RP2D in disease specific settings.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85234
- Rekrytering
- Research Site
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- Research Site
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- Research Site
-
Newport Beach, California, Förenta staterna, 92663
- Rekrytering
- Research Site
-
Santa Monica, California, Förenta staterna, 90404
- Rekrytering
- Research Site
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32224
- Rekrytering
- Research Site
-
Miami, Florida, Förenta staterna, 33136
- Indragen
- Research Site
-
Tampa, Florida, Förenta staterna, 33612
- Indragen
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Research Site
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Research Site
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Rekrytering
- Research Site
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Rekrytering
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Indragen
- Research Site
-
Winston-Salem, North Carolina, Förenta staterna, 27103
- Indragen
- Research Site
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97213
- Rekrytering
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- Rekrytering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Research Site
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Research Site
-
Round Rock, Texas, Förenta staterna, 78665
- Rekrytering
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Rekrytering
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria (Module 1)
-
Subjects must be at least 18 years of age
-
Subject must be diagnosed with one of the histologies below:
- NSCLC
- Colorectal adenocarcinoma
- HNSCC
- Pancreatic adenocarcinoma
- Breast cancer
- Ovarian cancer
- Any other solid tumor
-
Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A*02:01 positive (at least 1 allele)
-
Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options.
-
Subject has at least 1 measurable lesion
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria (Module 1)
- Any another primary malignancy within the 3 years prior to enrollment
- Known, active primary central nervous system (CNS) malignancy
- History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.
- History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.
- Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment.
- Any form of primary immunodeficiency.
- Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.
Key Inclusion Criteria (Module 2 - hematological malignancies)
- At least 18 years of age
- Diagnosis of AML or MDS that allows for efficacy assessments
- Confirmation of TP53 R175H variant mutation in cancer cells
- Subject must be HLA-A*02:01 positive (at least 1 allele)
- ECOG performance status of 0 to 1
Key Exclusion Criteria (Module 2 - hematological malignancy)
- Acute promyelocytic leukaemia or isolated extramedullary disease
- Another primary malignancy within 2 years (with exceptions)
- HSCT within 100 days or immunosuppression for GvHD within 4 weeks
- History of CNS or other extramedullary leukaemic involvement unless a lumbar puncture is negative for leukemic cells
- Prior stroke, ischemic attack, significant cardiac disease, heart failure
- Prior adoptive modified cell therapy
- Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: NT-175 for advanced malignancies
TCR T cell therapy product |
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsram: 28 days after infusion
|
Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175 |
28 days after infusion
|
|
Module 1, Part 1: Safety of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsram: Up to 24 months post-infusion
|
Incidence of Treatment Emergent Adverse Events (TEAE) Serious Adverse Events (SAE) |
Up to 24 months post-infusion
|
|
Module 1, Part 2: Preliminary anti-tumour activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsram: Up to 24 months after infusion
|
Per RECIST v1.1 determined by Investigator assessment:
|
Up to 24 months after infusion
|
|
Module 2: Safety of NT-175 in participants with haematological malignancies
Tidsram: Up to 28 days after infusion
|
- Incidence of dose-limiting toxicities (DLTs) after the infusion of NT-175 |
Up to 28 days after infusion
|
|
Module 2: Safety of NT-175 in participants with haematological malignancies
Tidsram: Up to 24 months after infusion
|
|
Up to 24 months after infusion
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Module 1, Part 1: Preliminary anti-tumor activity of NT-175 in participants with unresectable, advanced, and/or metastatic solid tumours
Tidsram: Up to 24 months after infusion
|
Per RECIST v1.1 determined by Investigator assessment:
|
Up to 24 months after infusion
|
|
Module 2: Evaluate preliminary anti-tumour activity in participants with AML or MDS
Tidsram: Up to 24 months after infusion
|
Per ELN 2022 criteria for AML and per IWG 2023 criteria for MDS by Investigator assessment:
By Investigator assessment:
|
Up to 24 months after infusion
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: AstraZeneca, AstraZeneca
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Genitala sjukdomar, kvinnor
- Lungsjukdomar
- Neoplasmer i endokrina körtel
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Kolonsjukdomar
- Lungneoplasmer
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Hudsjukdomar
- Bröstsjukdomar
- Carcinom
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Karcinom, skivepitel
- Hud- och bindvävssjukdomar
- Skivepitelcancer i huvud och hals
- Kolorektala neoplasmer
- Ovariella neoplasmer
- Bröstneoplasmer
- Karcinom, icke-småcellig lunga
Andra studie-ID-nummer
- NT-175-201
- D8690C00001 (Annan identifierare: AstraZeneca)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .